Insulin Dosing Calculator for Type 2 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new tool designed to manage insulin doses for hospitalized patients with type 2 diabetes. The goal is to determine if this calculator can stabilize blood sugar levels without causing excessive low blood sugar events. Participants will receive initial insulin doses using this calculator, and their results will be compared to those who receive standard care. This trial suits individuals admitted to the University of Washington Medical Centers with type 2 diabetes who already use insulin at home. As an unphased trial, this study offers an opportunity to contribute to innovative improvements in diabetes care.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, since participants must be receiving insulin therapy prior to admission, it seems likely that you will continue your current insulin regimen.
What prior data suggests that this insulin dosing calculator is safe for patients with type 2 diabetes?
Research shows that insulin dosing calculators can enhance patient safety and improve blood sugar management. Studies suggest these tools can prevent both low blood sugar (hypoglycemia) and high blood sugar (hyperglycemia). They provide accurate insulin doses based on factors such as blood sugar levels and body weight, simplifying and improving insulin management. Although specific safety data for the calculator used in this trial is unavailable, previous calculators have demonstrated safety, with no major safety issues reported.12345
Why are researchers excited about this trial?
Researchers are excited about the insulin dosing calculator for Type 2 Diabetes because it offers a personalized approach to insulin management. Unlike traditional methods where dosing can be a trial-and-error process, this calculator aims to tailor insulin doses specifically to each individual's needs. This could lead to more precise glucose control and reduce the risk of both high and low blood sugar episodes. By streamlining the dosing process, it also has the potential to make diabetes management easier and more efficient for patients.
What evidence suggests that this insulin dosing calculator is effective for managing blood glucose in type 2 diabetes?
Research has shown that insulin dosing calculators can help people with type 2 diabetes control their blood sugar more effectively. In this trial, participants will use an insulin dosing calculator to manage their insulin levels. One study found that these tools help manage blood sugar levels and enhance patient safety. They also simplify determining the correct insulin dose, which is particularly beneficial in busy hospitals. Previous research suggests that using these calculators reduces both high and low blood sugar episodes, making them a promising option for better diabetes management during hospital stays.12367
Who Is on the Research Team?
Hou-Hsien Chiang, MD, PhD
Principal Investigator
University of Washington
Are You a Good Fit for This Trial?
This trial is for patients admitted to the University of Washington Medical Centers who have type 2 or steroid-induced diabetes mellitus and were on insulin therapy before admission. It's not suitable for individuals outside these criteria.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive initial insulin doses by the calculator on hospital admission
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Initial insulin dosing using the calculator
Initial insulin dosing using the calculator is already approved in United States, European Union, Canada for the following indications:
- Type 2 diabetes mellitus
- Type 2 diabetes mellitus
- Type 2 diabetes mellitus
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator